Back to search

Peptide record

TPDB42933

HMP-S7 Anticancer standard
17 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB42933
HMP-S7
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 17-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
Sequence
SFIPRAKSTWLNNIKLL
Physicochemical Analysis
C94H153N25O23
DCEQGHMYV
L
2001.40
11.64
3
0
8
+3
-0.97
0.053
120.59
Mammalian: 1.9 hour Yeast: >20 hour E.coli: >10 hour
5500
274.81
5
Residue Composition
number
1
A
1
R
2
N
0
D
0
C
0
E
0
Q
0
G
0
H
2
I
3
L
2
K
0
M
1
F
1
P
2
S
1
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 1 R: 1 N: 2 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 2 L: 3 K: 2 M: 0 F: 1 P: 1 S: 2 T: 1 W: 1 Y: 0 V: 0
Chemical Descriptors
17
C94H153N25O23
2001.40
11.64
+3
-0.97
0.053
Free
L
Linear
Free
Anticancer
Human Milk
Evidence Records 4 records
Evidence 1 Activity

Activity

IC50
IC50 = 186 ± 37 µM
Anticancer
186

Target

Blood Cancer
Jurkat
Blood

Assay & Model

Trypan blue assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 184 ± 23 µM
Anticancer
184

Target

Blood Cancer
RS4 11
Blood

Assay & Model

Trypan blue assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021
Evidence 3 Activity

Activity

IC50
IC50 = 89 ± 24 µM
Anticancer
89

Target

Lymphoma Cancer
Raji
Blood

Assay & Model

Trypan blue assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021
Evidence 4 Activity

Activity

IC50
IC50 = 90 ± 14 µM
Anticancer
90

Target

Blood Cancer
Sup-B15
Blood

Assay & Model

Trypan blue assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021